Norman Radow, Managing Partner at Strul Medical Group, Joins Company's Board NASDAQ, TSX: NVCN VANCOUVER, Sept. 16, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Sept. 4, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,...
Read MoreAnnouncement Made at European Society of Cardiology Congress 2019 in Paris, France NASDAQ, TSX: NVCN VANCOUVER, Sept. 3, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Aug. 22, 2019 /CNW/ - ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum market...
Read MoreNASDAQ, TSX: NVCN Recent Highlights Received Guidance from FDA to explore a potential Humanitarian Device Exemption Pathway for Neovasc Reducer™ (the "Reducer") for CCS class IV patients and to meet for another Sprint discussion Closed Private Placement of Convertible Debt and Common Shares for Gross Proceeds of...
Read MorePresentation Scheduled for 11:30 am Eastern Time on August 8th NASDAQ, TSX: NVCN VANCOUVER, Aug. 5, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development...
Read MoreConference Call Scheduled for 4:30 pm Eastern Time on August 7th NASDAQ, TSX: NVCN VANCOUVER, Aug. 2, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, July 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...
Read More